JP2003512072A - ヒトスフィンゴシンキナーゼ遺伝子 - Google Patents

ヒトスフィンゴシンキナーゼ遺伝子

Info

Publication number: JP2003512072A
Authority: JP; Japan
Prior art keywords: seq; nucleic acid; sequence; recombinant; hsk
Prior art date: 1999-10-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2001533164A

Other languages

English (en)

Japanese (ja)

Inventor

アレン、ジャネット

ゴシンク、マーク

メレンデス、アリリオ、ジェイ

タカク、ラズロ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Warner Lambert Co LLC

Original Assignee

Warner Lambert Co LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-28

Filing date

2000-10-27

Publication date

2003-04-02

2000-10-27 Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC

2003-04-02 Publication of JP2003512072A publication Critical patent/JP2003512072A/ja

Status Pending legal-status Critical Current

Links

108010035597 sphingosine kinase Proteins 0.000 title claims abstract description 69
241000282414 Homo sapiens Species 0.000 title claims abstract description 39
150000007523 nucleic acids Chemical class 0.000 claims abstract description 83
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 81
239000013598 vector Substances 0.000 claims abstract description 79
102000039446 nucleic acids Human genes 0.000 claims abstract description 72
108020004707 nucleic acids Proteins 0.000 claims abstract description 72
ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 claims abstract description 68
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 60
229920001184 polypeptide Polymers 0.000 claims abstract description 54
238000000034 method Methods 0.000 claims abstract description 43
239000012634 fragment Substances 0.000 claims abstract description 22
230000000295 complement effect Effects 0.000 claims abstract description 20
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 9
238000012216 screening Methods 0.000 claims abstract description 9
241000124008 Mammalia Species 0.000 claims abstract description 6
102000040430 polynucleotide Human genes 0.000 claims description 40
108091033319 polynucleotide Proteins 0.000 claims description 40
239000002157 polynucleotide Substances 0.000 claims description 40
125000003729 nucleotide group Chemical group 0.000 claims description 37
239000002773 nucleotide Substances 0.000 claims description 35
150000001413 amino acids Chemical class 0.000 claims description 34
230000001580 bacterial effect Effects 0.000 claims description 32
DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims description 24
239000013615 primer Substances 0.000 claims description 22
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 21
125000003275 alpha amino acid group Chemical group 0.000 claims description 21
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 20
230000000692 anti-sense effect Effects 0.000 claims description 18
230000003321 amplification Effects 0.000 claims description 17
238000003199 nucleic acid amplification method Methods 0.000 claims description 17
238000006243 chemical reaction Methods 0.000 claims description 14
239000003112 inhibitor Substances 0.000 claims description 12
239000003153 chemical reaction reagent Substances 0.000 claims description 10
241000701447 unidentified baculovirus Species 0.000 claims description 10
238000012360 testing method Methods 0.000 claims description 9
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 5
239000003155 DNA primer Substances 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
230000035939 shock Effects 0.000 claims description 3
239000013592 cell lysate Substances 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
230000003204 osmotic effect Effects 0.000 claims description 2
239000008188 pellet Substances 0.000 claims description 2
238000000527 sonication Methods 0.000 claims description 2
230000009261 transgenic effect Effects 0.000 claims description 2
238000011830 transgenic mouse model Methods 0.000 claims description 2
108020000948 Antisense Oligonucleotides Proteins 0.000 abstract description 8
239000000074 antisense oligonucleotide Substances 0.000 abstract description 8
238000012230 antisense oligonucleotides Methods 0.000 abstract description 8
102000001253 Protein Kinase Human genes 0.000 abstract description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 4
230000016784 immunoglobulin production Effects 0.000 abstract description 3
101150084750 1 gene Proteins 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 123
230000014509 gene expression Effects 0.000 description 57
230000000694 effects Effects 0.000 description 39
108090000623 proteins and genes Proteins 0.000 description 36
235000001014 amino acid Nutrition 0.000 description 34
239000002299 complementary DNA Substances 0.000 description 31
241000238631 Hexapoda Species 0.000 description 22
239000000523 sample Substances 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 19
108020004414 DNA Proteins 0.000 description 18
108020001507 fusion proteins Proteins 0.000 description 18
102000037865 fusion proteins Human genes 0.000 description 18
239000000284 extract Substances 0.000 description 17
108010048367 enhanced green fluorescent protein Proteins 0.000 description 16
238000003556 assay Methods 0.000 description 15
235000018102 proteins Nutrition 0.000 description 13
108091026890 Coding region Proteins 0.000 description 12
239000011324 bead Substances 0.000 description 12
239000013604 expression vector Substances 0.000 description 12
230000004927 fusion Effects 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
238000001890 transfection Methods 0.000 description 12
241000894006 Bacteria Species 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 10
108091028043 Nucleic acid sequence Proteins 0.000 description 10
241000283973 Oryctolagus cuniculus Species 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 9
210000004899 c-terminal region Anatomy 0.000 description 9
230000012010 growth Effects 0.000 description 9
238000009396 hybridization Methods 0.000 description 9
238000002821 scintillation proximity assay Methods 0.000 description 9
210000002966 serum Anatomy 0.000 description 9
108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
201000001320 Atherosclerosis Diseases 0.000 description 7
OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
230000006698 induction Effects 0.000 description 7
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 7
239000003550 marker Substances 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
238000000746 purification Methods 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
108091000080 Phosphotransferase Proteins 0.000 description 6
241000700159 Rattus Species 0.000 description 6
230000027455 binding Effects 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000011575 calcium Substances 0.000 description 6
230000003197 catalytic effect Effects 0.000 description 6
238000010276 construction Methods 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
201000010099 disease Diseases 0.000 description 6
239000002609 medium Substances 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
102000020233 phosphotransferase Human genes 0.000 description 6
239000000047 product Substances 0.000 description 6
239000000758 substrate Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
102000016359 Fibronectins Human genes 0.000 description 5
108010067306 Fibronectins Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
108020005187 Oligonucleotide Probes Proteins 0.000 description 5
241000700605 Viruses Species 0.000 description 5
230000004913 activation Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000010367 cloning Methods 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
238000002955 isolation Methods 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000002751 oligonucleotide probe Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
230000008685 targeting Effects 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
238000000636 Northern blotting Methods 0.000 description 4
108010033276 Peptide Fragments Proteins 0.000 description 4
102000007079 Peptide Fragments Human genes 0.000 description 4
201000004681 Psoriasis Diseases 0.000 description 4
208000007536 Thrombosis Diseases 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
238000002820 assay format Methods 0.000 description 4
230000001363 autoimmune Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
230000030570 cellular localization Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000009826 distribution Methods 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
238000013537 high throughput screening Methods 0.000 description 4
230000006801 homologous recombination Effects 0.000 description 4
238000002744 homologous recombination Methods 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
239000003446 ligand Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
208000015122 neurodegenerative disease Diseases 0.000 description 4
230000008569 process Effects 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
238000003259 recombinant expression Methods 0.000 description 4
239000011347 resin Substances 0.000 description 4
229920005989 resin Polymers 0.000 description 4
239000000243 solution Substances 0.000 description 4
241000894007 species Species 0.000 description 4
108700028369 Alleles Proteins 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 3
244000063299 Bacillus subtilis Species 0.000 description 3
235000014469 Bacillus subtilis Nutrition 0.000 description 3
102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 description 3
VDRZDTXJMRRVMF-UONOGXRCSA-N D-erythro-sphingosine Natural products CCCCCCCCCC=C[C@@H](O)[C@@H](N)CO VDRZDTXJMRRVMF-UONOGXRCSA-N 0.000 description 3
208000032928 Dyslipidaemia Diseases 0.000 description 3
206010016654 Fibrosis Diseases 0.000 description 3
101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
208000017170 Lipid metabolism disease Diseases 0.000 description 3
YRXOQXUDKDCXME-YIVRLKKSSA-N N,N-dimethylsphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)N(C)C YRXOQXUDKDCXME-YIVRLKKSSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
108020004711 Nucleic Acid Probes Proteins 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol ( L-threo-sphinganine) Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
229940106189 ceramide Drugs 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000001514 detection method Methods 0.000 description 3
230000004761 fibrosis Effects 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229940043355 kinase inhibitor Drugs 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000004807 localization Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
201000006417 multiple sclerosis Diseases 0.000 description 3
239000002853 nucleic acid probe Substances 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
239000003757 phosphotransferase inhibitor Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000002987 primer (paints) Substances 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000003860 storage Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000014616 translation Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
238000001262 western blot Methods 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 2
CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 2
241000244203 Caenorhabditis elegans Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
OTKJDMGTUTTYMP-MSOLQXFVSA-N Erythro-dihydrosphingosine Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@H](N)CO OTKJDMGTUTTYMP-MSOLQXFVSA-N 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000663635 Homo sapiens Sphingosine kinase 1 Proteins 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
102000004889 Interleukin-6 Human genes 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
108091054455 MAP kinase family Proteins 0.000 description 2
102000043136 MAP kinase family Human genes 0.000 description 2
101000610214 Mus musculus Adenylyl-sulfate kinase Proteins 0.000 description 2
101100073488 Mus musculus Kcnn3 gene Proteins 0.000 description 2
101000974740 Mus musculus Small conductance calcium-activated potassium channel protein 1 Proteins 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
WSLBJQQQZZTFBA-MLUQOLBVSA-N PIP[4'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)OC1C(O)C(O)C(OP(O)(O)=O)[C@@H](O)C1O WSLBJQQQZZTFBA-MLUQOLBVSA-N 0.000 description 2
241001494479 Pecora Species 0.000 description 2
101710176384 Peptide 1 Proteins 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
108010091086 Recombinases Proteins 0.000 description 2
102000018120 Recombinases Human genes 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
102100039024 Sphingosine kinase 1 Human genes 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
238000012197 amplification kit Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000010828 elution Methods 0.000 description 2
230000013020 embryo development Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
208000018706 hematopoietic system disease Diseases 0.000 description 2
210000003630 histaminocyte Anatomy 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
239000012456 homogeneous solution Substances 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229940100601 interleukin-6 Drugs 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000011813 knockout mouse model Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
150000002617 leukotrienes Chemical class 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
229910052759 nickel Inorganic materials 0.000 description 2
238000005457 optimization Methods 0.000 description 2
108010071584 oxidized low density lipoprotein Proteins 0.000 description 2
230000037361 pathway Effects 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
150000004713 phosphodiesters Chemical class 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920002102 polyvinyl toluene Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
-1 pyro-glutamic acid compound Chemical class 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
102220240796 rs553605556 Human genes 0.000 description 2
238000007423 screening assay Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000013605 shuttle vector Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
230000001629 suppression Effects 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
FXEDIXLHKQINFP-UHFFFAOYSA-N 12-O-tetradecanoylphorbol-13-acetate Natural products CCCCCCCCCCCCCC(=O)OC1CC2(O)C(C=C(CO)CC3(O)C2C=C(C)C3=O)C4C(C)(C)C14OC(=O)C FXEDIXLHKQINFP-UHFFFAOYSA-N 0.000 description 1
238000011714 129 mouse Methods 0.000 description 1
CZIHNRWJTSTCEX-UHFFFAOYSA-N 2 Acetylaminofluorene Chemical compound C1=CC=C2C3=CC=C(NC(=O)C)C=C3CC2=C1 CZIHNRWJTSTCEX-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
241000776564 Acetobacter cerevisiae Species 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
102000005602 Aldo-Keto Reductases Human genes 0.000 description 1
108010084469 Aldo-Keto Reductases Proteins 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
108091007914 CDKs Proteins 0.000 description 1
101100244725 Caenorhabditis elegans pef-1 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
102100033029 Carbonic anhydrase-related protein 11 Human genes 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
108010051219 Cre recombinase Proteins 0.000 description 1
108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
101000867841 Homo sapiens Carbonic anhydrase-related protein 11 Proteins 0.000 description 1
101001075218 Homo sapiens Gastrokine-1 Proteins 0.000 description 1
101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 1
108091092878 Microsatellite Proteins 0.000 description 1
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
108091081548 Palindromic sequence Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
101150060820 Pfas gene Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
229930186873 Ponasterone Natural products 0.000 description 1
PJYYBCXMCWDUAZ-YKDQUOQBSA-N Ponasterone A Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CCC(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 PJYYBCXMCWDUAZ-YKDQUOQBSA-N 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
101001062854 Rattus norvegicus Fatty acid-binding protein 5 Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
101150060587 SK gene Proteins 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
208000002474 Tinea Diseases 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
ZKHQWZAMYRWXGA-MVKANHKCSA-N [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxy(32P)phosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO[32P](O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-MVKANHKCSA-N 0.000 description 1
SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
238000007792 addition Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000012911 assay medium Substances 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000010310 bacterial transformation Effects 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
229950004398 broxuridine Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
235000020964 calcitriol Nutrition 0.000 description 1
239000011612 calcitriol Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000015861 cell surface binding Effects 0.000 description 1
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
239000013522 chelant Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
208000027744 congestion Diseases 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
230000001517 counterregulatory effect Effects 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
230000003436 cytoskeletal effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
231100000221 frame shift mutation induction Toxicity 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
238000010363 gene targeting Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
239000006451 grace's insect medium Substances 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
239000011539 homogenization buffer Substances 0.000 description 1
102000054896 human PML Human genes 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000014726 immortalization of host cell Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000012194 insect media Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000000021 kinase assay Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000000670 ligand binding assay Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007762 localization of cell Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
239000005445 natural material Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000011824 nuclear material Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
238000002823 phage display Methods 0.000 description 1
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
238000005424 photoluminescence Methods 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
150000003102 ponasterones Chemical class 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000000941 radioactive substance Substances 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000000384 rearing effect Effects 0.000 description 1
210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
210000003583 retinal pigment epithelium Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
210000003518 stress fiber Anatomy 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
108010004909 sulfurylase kinase Proteins 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
239000012096 transfection reagent Substances 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
230000017105 transposition Effects 0.000 description 1
239000000717 tumor promoter Substances 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Microbiology (AREA)

JP2001533164A 1999-10-28 2000-10-27 ヒトスフィンゴシンキナーゼ遺伝子 Pending JP2003512072A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US16230799P	1999-10-28	1999-10-28
US60/162,307		1999-10-28
US18052500P	2000-02-07	2000-02-07
US60/180,525		2000-02-07
PCT/EP2000/009498 WO2001031029A2 (fr)	1999-10-28	2000-10-27	Gene de la sphingosine kinase humaine

Publications (1)

Publication Number	Publication Date
JP2003512072A true JP2003512072A (ja)	2003-04-02

Family

ID=26858638

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2001533164A Pending JP2003512072A (ja)	1999-10-28	2000-10-27	ヒトスフィンゴシンキナーゼ遺伝子

Country Status (7)

Country	Link
EP (1)	EP1228221A2 (fr)
JP (1)	JP2003512072A (fr)
AU (1)	AU1020201A (fr)
BR (1)	BR0015138A (fr)
CA (1)	CA2389127A1 (fr)
MX (1)	MXPA02004294A (fr)
WO (1)	WO2001031029A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2022512843A (ja) *	2018-10-21	2022-02-07	北京双因生物科技有限公司	スフィンゴシンキナーゼ１とその融合タンパク質およびその使用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6423527B1 (en)	1997-09-29	2002-07-23	Children's Hospital Medical Center Of Northern California	Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
AU3828301A (en) *	2000-02-14	2001-08-27	Curagen Corp	Novel sphingosine kinases
AUPQ744700A0 (en) *	2000-05-11	2000-06-01	Medvet Science Pty. Ltd.	A method of treatment and agents useful for same
WO2002000887A1 (fr) *	2000-06-28	2002-01-03	Medvet Science Pty Ltd	Nouveaux variants moleculaires et leurs utilisations
US6610534B2 (en) *	2000-10-05	2003-08-26	Novartis Ag	Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
ES2523856T3 (es)	2000-12-22	2014-12-02	Lpath, Inc.	Anticuerpos de esfingosina-1-fosfato para el tratamiento de enfermedades asociadas con elevadas concentraciones de esfingolípidos
JP4667749B2 (ja) *	2002-01-17	2011-04-13	チルドレンズホスピタルアンドリサーチセンターアットオークランド	スフィンゴ脂質代謝および／またはシグナル伝達の調節のための組成物および方法
US7674580B2 (en)	2002-01-17	2010-03-09	Children's Hospital & Research Center At Oakland	Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
US9274129B2 (en)	2006-05-31	2016-03-01	Lpath, Inc.	Methods and reagents for detecting bioactive lipids
US9274130B2 (en)	2006-05-31	2016-03-01	Lpath, Inc.	Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9217749B2 (en)	2006-05-31	2015-12-22	Lpath, Inc.	Immune-derived moieties reactive against lysophosphatidic acid
ES2524059T3 (es)	2006-10-27	2014-12-03	Lpath, Inc.	Composiciones y procedimientos de unión a esfingosina-1-fosfato
US8871202B2 (en)	2008-10-24	2014-10-28	Lpath, Inc.	Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
CN113295793B (zh) *	2021-05-20	2022-11-04	复旦大学附属中山医院	预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998054963A2 (fr) *	1997-06-06	1998-12-10	Human Genome Sciences, Inc.	207 proteines secretees humaines
CA2329124A1 (fr) *	1998-05-26	1999-12-02	Office Of The Dean Of Research And Graduate Education	Clonage, expression et procedes d'utilisation de la sphingosine kinase
AU2899900A (en) *	1999-03-02	2000-09-21	Nps Allelix Corp.	Cloned human sphingosine kinase homologues
JP2002538827A (ja) *	1999-03-18	2002-11-19	インサイト・ファーマスーティカルズ・インコーポレイテッド	細胞内リン酸化反応のレギュレータ
JP2002543831A (ja) *	1999-05-13	2002-12-24	ジョンソン・アンド・ジョンソン・リサーチ・プロプライエタリー・リミテッド	スフィンゴシンキナーゼ

2000
- 2000-10-27 BR BR0015138-6A patent/BR0015138A/pt not_active IP Right Cessation
- 2000-10-27 EP EP00971299A patent/EP1228221A2/fr not_active Withdrawn
- 2000-10-27 CA CA002389127A patent/CA2389127A1/fr not_active Abandoned
- 2000-10-27 MX MXPA02004294A patent/MXPA02004294A/es unknown
- 2000-10-27 WO PCT/EP2000/009498 patent/WO2001031029A2/fr not_active Application Discontinuation
- 2000-10-27 AU AU10202/01A patent/AU1020201A/en not_active Abandoned
- 2000-10-27 JP JP2001533164A patent/JP2003512072A/ja active Pending

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2022512843A (ja) *	2018-10-21	2022-02-07	北京双因生物科技有限公司	スフィンゴシンキナーゼ１とその融合タンパク質およびその使用

Also Published As

Publication number	Publication date
CA2389127A1 (fr)	2001-05-03
EP1228221A2 (fr)	2002-08-07
AU1020201A (en)	2001-05-08
WO2001031029A2 (fr)	2001-05-03
WO2001031029A3 (fr)	2002-02-28
BR0015138A (pt)	2002-07-16
MXPA02004294A (es)	2002-10-31

Publication	Publication Date	Title
EP1051500B1 (fr)	2005-08-17	Diagnostic et traitement de maladies associees a aur1 et/ou aur2
JP2003512072A (ja)	2003-04-02	ヒトスフィンゴシンキナーゼ遺伝子
US5759811A (en)	1998-06-02	Mutant human hedgehog gene
CA2207581A1 (fr)	1996-06-20	Probine tyrosine kinase (pyk2), son clonage par adnc et son utilisation
US7303895B1 (en)	2007-12-04	Choline transport like (CTL) membrane proteins involved in choline transport
JP2007195551A (ja)	2007-08-09	セマホリンレセプター
AU2001263952B2 (en)	2005-07-21	Tumour suppressor and uses thereof
AU2001263952A1 (en)	2002-03-07	Tumour suppressor and uses thereof
JPH11500606A (ja)	1999-01-19	核タンパク質セリン／スレオニンキナーゼ
JP2000506396A (ja)	2000-05-30	ホスファチジルイノシトール―３′―キナーゼ関連タンパク質をコードするヌクレオチド配列及びその利用
US6110718A (en)	2000-08-29	Mammalian putative phosphatidylinositol-4-phosphate-5-kinase
US6797513B2 (en)	2004-09-28	Nucleic acid encoding CLK2 protein kinases
US20040005688A1 (en)	2004-01-08	Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof
WO2004048565A1 (fr)	2004-06-10	Proteine associee a l'apoptose et son utilisation
WO2000012754A1 (fr)	2000-03-09	Procede d'identification de substances pour le traitement de troubles induits par la c-jun
CA2319037A1 (fr)	1999-09-23	Identification de facteurs regulant l'interaction entre des proteines g heterotrimeres et des proteines g monomeres
JP2004522413A (ja)	2004-07-29	単離ヒトキナーゼタンパク質、ヒトキナーゼタンパク質をコード化する核酸分子及びその使用
US20030036184A1 (en)	2003-02-20	Polypeptides exhibiting PDE7 activity and their use for selecting compounds which inhibit PDE 7 enzyme activity
US6673570B1 (en)	2004-01-06	Smad associating polypeptides
JP2004500848A (ja)	2004-01-15	新しいモータータンパク質とその使用法
US20060286622A1 (en)	2006-12-21	Polypeptides exhibiting PDE7 activity and their use for selecting compounds which inhibit PDE 7 enzyme activity
US20040096939A1 (en)	2004-05-20	Modifier of organelle metabolism
US20020012964A1 (en)	2002-01-31	Cell cycle regulating factor
JP2002514173A (ja)	2002-05-14	グリコーゲンを標的とするタンパク質
US20040106127A1 (en)	2004-06-03	Novel gene and protein encoded by the gene

JP2003512072A - ヒトスフィンゴシンキナーゼ遺伝子 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (5)

Publications (1)

Family

ID=26858638

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (14)

Family Cites Families (5)

Cited By (1)

Also Published As

Similar Documents